TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10747210

Group type: COMPARATOR
Intervention: Epidural morphine 1 mg after surgery with PCA delivering morphine 0.2 mg h‐1, 0.2 mg per bolus.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine 1 mg plus ketamine 5 mg after surgery with PCA delivering morphine 0.2 mg + ketamine 0.5 mg h‐1, morphine 0.2 mg + ketamine 0.5 mg per bolus.
Number of subjects: 60
Study: 8721941

Group type: EXPERIMENTAL
Intervention: Therapeutic shoes (Podiabetes by Buratto Italy)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Own shoes (Control group)
Number of subjects: 69
Study: 2406462

Group type: EXPERIMENTAL
Intervention: Double‐pigtail stents placed before extracorporeal shock wave lithotripsy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no stents)
Number of subjects: 50
Study: 7191313

Group type: EXPERIMENTAL
Intervention: Acemetacin (180 mg daily in three divided doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indometacin (150 mg daily in three divided doses)
Number of subjects: 40
Study: 6507551

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used during anterior capsulotomy and nuclear expression
Number of subjects: 181

Group type: COMPARATOR
Intervention: No sodium hyaluronate used
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used later in the procedure
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used
Number of subjects: 181
Study: 30832646

Group type: EXPERIMENTAL
Intervention: Screening for mental health disorders using validated tools
Number of subjects: 1015
Study: 30305073

Group type: EXPERIMENTAL
Intervention: 23G system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20G system
Number of subjects: 60
Study: 26692375

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study: 25231604

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional anatomical landmarks
Number of subjects: 50
Study: 21862446

Group type: EXPERIMENTAL
Intervention: Positivity motivation in social cognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural activation in response to social targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OFC activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intimacy with the social target
Number of subjects: 0
Study: 20096136

Group type: EXPERIMENTAL
Intervention: Manual Therapy according to the Utrecht School of Manual Therapy (MTU) for six weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Physical Therapy (standard care, mainly active exercise therapy) for six weeks
Number of subjects: 180
Study: 16859993

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diclofenac (both treatments)
Number of subjects: 12
Study: 16053779

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 54
Study: 12400712

Group type: EXPERIMENTAL
Intervention: Human fibroblast-derived dermis (HFDD) plus saline-moistened gauze
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline-moistened gauze alone (CT)
Number of subjects: 28
Study: 10464875

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nebulized normal saline (control group)
Number of subjects: 30
Study: 7889634

Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of 95% ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Background alcohol intake
Number of subjects: 12
Study: 2198135

Group type: EXPERIMENTAL
Intervention: Nasal CPAP (range 2.5 to 12.5 cm H2O)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nasal oxygen (O2) at 4 LPM
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (air at 4 LPM)
Number of subjects: 8
Study: 347885

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 95
Study: 30852915

Group type: EXPERIMENTAL
Intervention: 0.2% xanthan gum eye drops (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% carboxymethylcellulose (group 2)
Number of subjects: 30
Study: 31345677

Group type: EXPERIMENTAL
Intervention: Multiple target vegetables (3 vegetables)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single target vegetable (1 vegetable)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison group (no change in eating habits)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dinner meal intake
Number of subjects: 32
Study: 27920261

Group type: EXPERIMENTAL
Intervention: rTMS combined with sensory cueing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rTMS alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 60
Study: 25662596

Group type: EXPERIMENTAL
Intervention: VCB regimen (cisplatin 80 mg/m², oral vinorelbine 60 mg/m², and bevacizumab 15 mg/kg) followed by DGB regimen (docetaxel 75 mg/m², gemcitabine 1100 mg/m², and bevacizumab 15 mg/kg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: DCB regimen (cisplatin 80 mg/m², docetaxel 75 mg/m², and bevacizumab 15 mg/kg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: VCB regimen
Number of subjects: 77

Group type: COMPARATOR
Intervention: DCB regimen
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 77
Study: 23799908

Group type: EXPERIMENTAL
Intervention: Udenafil 50 mg twice daily for 4 weeks, then 100 mg twice daily for 8 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Udenafil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22938690

Group type: EXPERIMENTAL
Intervention: Mannose-binding lectin deficiency (MBL levels ≤ 500 ng/ml)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Patients with cystatin C increase of ≥ 10%
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Creatinine-based CIN
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cystatin C-based CIN
Number of subjects: 246
Study: 19633794

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17668527

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5%/clindamycin 1% gel as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5%/clindamycin 1% gel in combination with adapalene gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapalene gel monotherapy
Number of subjects: 0
Study: 15496273

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines in development for mobilization
Number of subjects: 0
Study: 10773555

Group type: EXPERIMENTAL
Intervention: Heart transplant recipients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Heart transplant candidates
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 75
Study: 8921927

Group type: EXPERIMENTAL
Intervention: Specialized diet with adjusted energy intake, increased fish meals and antioxidants
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care without specialized diet
Number of subjects: 109
Study: 1316721

Group type: EXPERIMENTAL
Intervention: Coupon offer
Number of subjects: 2109

Group type: EXPERIMENTAL
Intervention: Referral reminder letter
Number of subjects: 2109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2109

Group type: EXPERIMENTAL
Intervention: Lay-counseling coupon offer
Number of subjects: 2109

Group type: EXPERIMENTAL
Intervention: Lay-counseling reminder letter
Number of subjects: 2109
Study: 4035294

Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30308004

Group type: EXPERIMENTAL
Intervention: Traditional aerobic and resistance exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flywheel exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-exercise (control group)
Number of subjects: 18
Study: 28834483

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target systolic blood pressure < 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (target systolic blood pressure < 140 mm Hg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 9361
Study: 25183702

Group type: EXPERIMENTAL
Intervention: Auricular electrical stimulation combined with auricular acupressure
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham acupoint stimulation
Number of subjects: 134
Study: 22922526

Group type: EXPERIMENTAL
Intervention: High partner influence
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low partner influence
Number of subjects: 44
Study: 21944067

Group type: EXPERIMENTAL
Intervention: Custom-molded foot orthosis (FO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balanced traditional orthosis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Full-contact orthosis
Number of subjects: 16
Study: 18324527

Group type: EXPERIMENTAL
Intervention: Tomato extract (45 mg lycopene/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tomato juice (45 mg lycopene/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17163232

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily (regimen A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily (regimen B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily plus hydrochlorothiazide 25 mg once daily (regimen C)
Number of subjects: 24
Study: 14604159

Group type: EXPERIMENTAL
Intervention: 1 year of anti-epileptic drug therapy (AED)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 2 years of anti-epileptic drug therapy (AED)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Abnormal CT prior to AED withdrawal
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Abnormal EEG prior to AED withdrawal
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of persistent/calcified CT lesion and abnormal EEG prior to AED withdrawal
Number of subjects: 115

Group type: COMPARATOR
Intervention: 1 vs. 2 years of AED therapy
Number of subjects: 115
Study: 10985512

Group type: EXPERIMENTAL
Intervention: Atropine 500 mcg intramuscularly
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline 1 mL intramuscularly
Number of subjects: 20
Study: 8874574

Group type: EXPERIMENTAL
Intervention: Pre-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after induction of general anaesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups received paracetamol 15-20 mg/kg rectally when admitted to the recovery ward
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 1393167

Group type: EXPERIMENTAL
Intervention: Tape-recorded consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non tape-recorded consultations
Number of subjects: 0
Study: 4001842

Group type: EXPERIMENTAL
Intervention: 1 g of unconjugated chenodeoxycholic acid (CDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 0
Study: 30285499

Group type: EXPERIMENTAL
Intervention: Patient Advocate (PA) intervention, which includes meeting with patients before medical visits, attending appointments, and reviewing provider instructions.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Provider focus groups and interviews (qualitative analysis).
Number of subjects: 24
Study: 29732624

Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation 2: Short Version for Adults (R&R2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 101
Study: 25851059

Group type: EXPERIMENTAL
Intervention: 1% acetic acid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study: 24226808

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI)
Number of subjects: 14821

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 14821

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14821
Study: 22622852

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (20 mg)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Intravenous piritramide PCA (2 mg piritramide/ml 0.9 % saline)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both treatments (oral oxycodone and PCA)
Number of subjects: 239
Study: 20397131

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No restricted diffusion on DWI
Number of subjects: 12
Study: 18062829

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg, 200 microg, or 300 microg Se as Se-enriched yeast)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 16027558

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 14674116

Group type: EXPERIMENTAL
Intervention: Iscador QuS administered s.c. twice a week for 3 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intron A administered twice a week in cervical injections for 3 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study: 10757101

Group type: EXPERIMENTAL
Intervention: Structured medical advice during ICU hospitalization and follow-up in the second, third, and fourth week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ordinary anti-tobacco advice
Number of subjects: 90
Study: 8186159

Group type: EXPERIMENTAL
Intervention: VIP (ifosfamide, cisplatin, vinblastine)
Number of subjects: 136

Group type: COMPARATOR
Intervention: PV (cisplatin, vinblastine)
Number of subjects: 136
Study: 2451412

Group type: EXPERIMENTAL
Intervention: Oxendolone + Bunazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxendolone
Number of subjects: 0
Study: 29664106

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus therapeutic exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyaluronate plus therapeutic exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Therapeutic exercise alone (control group with saline injection)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical Component Summary‐36 and Mental Component Summary‐36 scores
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (saline injection) vs Hyaluronate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and X-ray images
Number of subjects: 60
Study: 26811535

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg per day
Number of subjects: 396

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg per day
Number of subjects: 396
Study: 26409883

Group type: EXPERIMENTAL
Intervention: Multidisciplinary programme (MD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 203
Study: 23488643

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 21323255

Group type: EXPERIMENTAL
Intervention: Peer review intervention group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (self-assessment)
Number of subjects: 47
Study: 19815828

Group type: EXPERIMENTAL
Intervention: Herpes zoster patients
Number of subjects: 7760

Group type: COMPARATOR
Intervention: Comparison cohort
Number of subjects: 7760

Group type: EXPERIMENTAL
Intervention: Herpes zoster ophthalmicus
Number of subjects: 7760
Study: 17988824

Group type: EXPERIMENTAL
Intervention: Remifentanil-midazolam
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fentanyl-midazolam
Number of subjects: 19
Study: 15555291

Group type: EXPERIMENTAL
Intervention: Capecitabine combined with TACE
Number of subjects: 49

Group type: COMPARATOR
Intervention: TACE only
Number of subjects: 49
Study: 11576818

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Prescription from a gynecologist
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Mammogram a year prior to initiation
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors (SSRI) antidepressants 3 months prior to initiation
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Enrollment in the health plan for less than 3 years
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Year of cohort entry (1994)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Year of cohort entry (1995)
Number of subjects: 992
Study: 9046380

Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cues
Number of subjects: 30
Study: 8582196

Group type: EXPERIMENTAL
Intervention: Oestrogen-based hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certain progesterone metabolites
Number of subjects: 0
Study: 2570798

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 16
Study: 71209

Group type: EXPERIMENTAL
Intervention: CVP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ABP (adriamycin, bleomycin, and prednisone)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CVP (after crossover for progression or relapse)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ABP (after crossover for progression or relapse)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CVP and ABP (sequentially alternated in subsequent study)
Number of subjects: 57
Study: 31576607

Group type: EXPERIMENTAL
Intervention: Almond consumption (20% of daily energy for 16 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calorie-matched snack (control group)
Number of subjects: 28
Study: 28167383

Group type: EXPERIMENTAL
Intervention: Group presence
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Category labels
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Generic statements
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control
Number of subjects: 203
Study: 26312522

Group type: EXPERIMENTAL
Intervention: Nursing guidance protocol about bed bath
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine information from the unit
Number of subjects: 120
Study: 23949731

Group type: EXPERIMENTAL
Intervention: IVF/ICSI with PGS
Number of subjects: 113

Group type: COMPARATOR
Intervention: IVF/ICSI without PGS (control)
Number of subjects: 113
Study: 22097978

Group type: EXPERIMENTAL
Intervention: Pulsatile normothermia CPB (PNCPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonpulsatile normothermia CPB (NNCPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonpulsatile moderate hypothermia CPB (NHCPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulsatile moderate hypothermia CPB (PHCPB)
Number of subjects: 60
Study: 18753185

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI), n=81
Number of subjects: 100

Group type: COMPARATOR
Intervention: Histamine-2 receptor antagonist (H2RA), n=19
Number of subjects: 100
Study: 16670069

Group type: EXPERIMENTAL
Intervention: Solvent/detergent (SD) plasma
Number of subjects: 17
Study: 15799926

Group type: EXPERIMENTAL
Intervention: Stentless aortic valve replacement (Freestyle)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stented aortic valve replacement (Mosaic)
Number of subjects: 16
Study: 11010599

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory effort (targeted peak inhalation flow 30 L/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Submaximal inspiratory effort (targeted peak inhalation flow 15 L/min)
Number of subjects: 10
Study: 9283989

Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Loratadine 10 mg once daily
Number of subjects: 84
Study: 8356856

Group type: EXPERIMENTAL
Intervention: Buprenorphine (3.0 micrograms/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine (100 micrograms/kg)
Number of subjects: 20
Study: 3322310

Group type: EXPERIMENTAL
Intervention: 3-palmitoyl-(+)‐catechin at a dose of 1500 mg daily (500 mg t.d.s.) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-palmitoyl-(+)‐catechin
Number of subjects: 0
Study: 30012380

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=120)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=100)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Sham acupuncture (n=121)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Sham acupuncture (n=100)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=120) and (n=100)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Sham acupuncture (n=121) and (n=100)
Number of subjects: 441
Study: 27618810

Group type: EXPERIMENTAL
Intervention: Family health history (FHH) risk assessment tool
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Family health history (FHH) feedback
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Above-average family disease risk
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no FHH feedback initially)
Number of subjects: 150
Study: 24693784

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation and single PEEK Cage
Number of subjects: 126

Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation and single PEEK Cage
Number of subjects: 126